Goldline Pharmaceutical IPO Final Subscription Status
Final subscription data from BSE & NSE with category-wise breakdowns
Subscription (Shares)
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 5,40,000 | 9,73,17,000 | 180.22 |
| NII | 3,90,000 | 64,83,15,000 | 1,662.35 |
| bNII (>10 Lakh) | 2,60,000 | 43,22,10,000 | 1,662.35 |
| sNII (2-10 Lakh) | 1,30,000 | 21,61,05,000 | 1,662.35 |
| Retail | 9,00,000 | 79,26,12,000 | 880.68 |
| TOTAL | 18,30,000 | 1,53,82,44,000 | 840.57 |
Application Breakup
| Category | Reserved | Applications | Times |
|---|---|---|---|
| NII | 43 | 1,08,052 | 2,512.84 |
| bNII (>10 Lakh) | 29 | 18,009 | 621.00 |
| sNII (2-10 Lakh) | 14 | 36,018 | 2,572.71 |
| Retail | 300 | 2,64,204 | 880.68 |
| TOTAL | 386 | 4,26,283 | 1,104.36 |
Subscription (Crores)
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIB | 2.32 | 418.46 | 180.22 |
| NII | 1.68 | 2,787.75 | 1,662.35 |
| bNII (>10 Lakh) | 1.12 | 1,858.50 | 1,662.35 |
| sNII (2-10 Lakh) | 0.56 | 929.25 | 1,662.35 |
| Retail | 3.87 | 3,408.23 | 880.68 |
| TOTAL | 7.87 | 6,614.45 | 840.57 |
Day-wise Subscription
End-of-day subscription.
| Day | QIB | NII | bNII | sNII | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 12 May | 1.31x | 24.46x | 24.46x | 24.46x | 34.07x | 22.35x |
| Day 2 13 May | 1.31x | 146.48x | 146.48x | 146.48x | 139.51x | 100.21x |
| Day 3 14 May | 180.22x | 1662.35x | 1662.35x | 1662.35x | 880.68x | 840.57x |
Estimated Allotment Chance
How Goldline Pharmaceutical’s demand compares with recent SME IPOs
Final multiples against the 192 SME IPOs listed in the last 12 months.
| Category | Goldline Pharmaceutical | SME median | Higher than |
|---|---|---|---|
| Overall | 841x | 3.98x | 100% of 192 |
| QIB | 180x | 14.69x | 91% of 163 |
| NII (HNI) | 1662x | 5.32x | 100% of 192 |
| Retail | 881x | 3.5x | 100% of 192 |
Of the 44 recent SME IPOs that finished 100x or more subscribed, 91% opened above the issue price, with a median listing-day move of +42.9%. Goldline Pharmaceutical itself listed at +39%.
Goldline Pharmaceutical IPO Subscription — Detailed Analysis
Where Goldline Pharmaceutical Subscription Finished
Goldline Pharmaceutical IPO was subscribed 840.57 times overall by the close of bidding — a heavily oversubscribed level that signals strong investor demand.
Goldline Pharmaceutical IPO Subscription — FAQs
See also: reading the subscription table · allotment chances · allotment process
Explore More
Quick links to all IPO sections